Table 1.

Characteristics of all randomized patients versus patients with genotyping results

CharacteristicAll randomized patients (N = 572) N (%)Patients with FCGR2A results (N = 286) N (%)Patients with FCGR3A results (N = 288) N (%)
Age—median (range) in years63.2 (29 –88)63.4 (29–86)63.4 (29–86)
Male368 (64)196 (68)198 (69)
ECOG Performance status
 0136 (24)75 (26)75 (26)
 1302 (53)162 (57)163 (57)
 2134 (23)49 (17)50 (17)
Site of primary
 Colon only332 (58)177 (62)178 (62)
 Rectum only133 (23)55 (19)55 (19)
 Colon and rectum107 (19)54 (19)55 (19)
Any prior radiotherapy202 (35)85 (30)85 (30)
Prior chemotherapy
 Prior adjuvant therapy211 (37)107 (37)108 (38)
 Number of regimens 1–2104 (18)50 (18)50 (17)
  3217 (38)111 (39)112 (39)
  4+241 (44)125 (43)126 (44)
Sites of disease
 Liver463 (81)234 (82)236 (82)
 Lung368 (64)177 (62)178 (62)
 Nodes247 (43)128 (45)129 (45)
 Ascites86 (15)42 (15)42 (15)
Number of sites of disease
 193 (16)51 (18)51 (18)
 2153 (27)81 (28)82 (29)
 3173 (30)83 (29)84 (29)
 ≥4153 (27)71 (25)71 (25)
KRAS mutation
 KRAS mutant164 (29)105 (37)106 (37)
 KRAS wild-type230 (40)148 (52)149 (52)
 Missing178 (31)33 (12)33 (12)
Treatment
 Cetuximab + BSC287 (50)137 (48)138 (48)
 BSC Only285 (50)149 (52)150 (52)
  • Abbreviations: BSC, best supportive care; ECOG: Eastern Cooperative Oncology Group.